COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Protocol No
PROTHENA-NEOD001-301
Principal Investigator
Anita D'Souza
Phase
III
Summary
The purpose of this study is to evaluate whether birtamimab, when given along with standard of care chemotherapy, will improve survival in subjects with Mayo Stage IV AL amyloidosis.
Description
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL